12:00 AM
 | 
Jun 04, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/1 cls
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) Baird Thomas Russo Downgrade Neutral (from overweight) -4% $26.73
Russo downgraded after revisiting the risk/reward of a potential takeout of Amylin. He believes that while it's still more likely that the diabetes company will be acquired for $30 or more per share, the potential downside for investors without an acquisition is that Amylin's share price drops into the mid-teens. Russo recommended "locking in gains" given the "magnitude" of the downside.
Dyax Corp. (NASDAQ:DYAX) Leerink Joseph Schwartz Upgrade Outperform (from market perform) 5% $1.80
Schwartz also raised his target to $4 from $1.65 on "achievable" sales estimates for hereditary angioedema (HAE) drug Kalbitor ecallantide, as well as upcoming catalysts and "significant upside"...

Read the full 861 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >